<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572000</url>
  </required_header>
  <id_info>
    <org_study_id>111040 (HPV-022 PRI)</org_study_id>
    <nct_id>NCT00572000</nct_id>
  </id_info>
  <brief_title>Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule</brief_title>
  <acronym>HPV-022 PRI</acronym>
  <official_title>Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute for Control of Vaccine and Biologicals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute for Control of Vaccine and Biologicals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the occurrence of serious adverse events (SAEs) as&#xD;
      well as evaluate the occurrence of solicited local and solicited general symptoms and the&#xD;
      occurrence of medically significant conditions reported throughout the study period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the occurrence of serious adverse events (SAEs) throughout the study</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of unsolicited symptoms as well as the occurrence of medically significant conditions.</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Human Papillomavirus (HPV) Vaccine</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV-16/18 L1 VLP AS04 vaccine</intervention_name>
    <description>Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who the investigator believes that they can and will comply with the&#xD;
             requirements of the protocol (e.g., completion of the diary cards, return for&#xD;
             vaccination visits and for the follow-up visit) should be enrolled in the study.&#xD;
&#xD;
             • The female subject should be:&#xD;
&#xD;
          -  married&#xD;
&#xD;
          -  of Vietnamese origin, residing in Vietnam, and&#xD;
&#xD;
          -  between, and including, 25 to 40 years of age at the time of the first vaccination.&#xD;
&#xD;
               -  Written informed consent obtained from the subject (prior to enrolment).&#xD;
&#xD;
               -  Healthy subjects as established by medical history and clinical examination&#xD;
                  before entering into the study.&#xD;
&#xD;
               -  Subjects must have a negative urine pregnancy test.&#xD;
&#xD;
               -  Subjects of childbearing potential (i.e. active menstrual cycle) at the time of&#xD;
                  study entry:&#xD;
&#xD;
          -  must not be pregnant&#xD;
&#xD;
          -  and must be abstinent (and if so, this must be documented in the source documents at&#xD;
             each vaccination visit)&#xD;
&#xD;
          -  or must be using adequate contraceptive precautions (i.e. intrauterine contraceptive&#xD;
             device, oral contraceptives, diaphragm or condom in combination with contraceptive&#xD;
             jelly, cream or foam, progestogen-only implantable cutaneous hormonal patch or&#xD;
             injectable contraceptives) for 30 days prior to vaccination and must agree to continue&#xD;
             such precautions for one month after completion of the vaccination series.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug or vaccine) other than the&#xD;
             study vaccine within 30 days preceding the first dose of study vaccine, or planned use&#xD;
             during the study period and up to one month after the last vaccine dose.&#xD;
&#xD;
               -  Subjects who have delivered recently or breastfeeding women must have completed a&#xD;
                  period of at least 3 months post-pregnancy and should not be breast-feeding in&#xD;
                  order to be enrolled in the study.&#xD;
&#xD;
        Planning to become pregnant or likely to become pregnant (as determined by the&#xD;
        investigator) or planning to discontinue contraceptive precautions during the study period.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other&#xD;
             immune-modifying drugs on 14 consecutive days within six months prior to the first&#xD;
             vaccine dose and up to one month after the last dose of the vaccine. (For&#xD;
             corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled&#xD;
             and topical steroids are allowed).&#xD;
&#xD;
          -  Planned administration/administration of a vaccine not foreseen by the study protocol&#xD;
             within 30 days before (Days - 1 to - 30) and 30 days (i.e. Days 0 - 29) after the&#xD;
             first dose of vaccine. However, the administration of tetanus toxoid vaccine up to 8&#xD;
             days before the first dose of study vaccine is allowed. Enrolment will be deferred&#xD;
             until the subject is outside of specified window.&#xD;
&#xD;
          -  Previous vaccination against HPV or planned administration of any HPV vaccine other&#xD;
             than that foreseen by the study protocol during the study period.&#xD;
&#xD;
          -  Any medically diagnosed or suspected immunodeficient condition such as human&#xD;
             immunodeficiency virus (HIV) infection based on medical history and physical&#xD;
             examination (no laboratory testing required).&#xD;
&#xD;
          -  History of allergic disease, suspected allergy or reactions likely to be exacerbated&#xD;
             by any component of the study vaccines, e.g. AS04, aluminium, MPL.&#xD;
&#xD;
          -  Hypersensitivity to latex (found in syringe-tip cap and plunger).&#xD;
&#xD;
          -  Known acute or chronic, clinically significant system conditions, e.g.&#xD;
             neurologic,pulmonary, cardiovascular, hepatic, renal functional abnormality or&#xD;
             psychiatric disorders, as determined by medical history, physical examination or&#xD;
             previous laboratory tests.&#xD;
&#xD;
          -  History of chronic condition(s) requiring treatment such as cancer, chronic hepatic or&#xD;
             kidney disease(s), diabetes, or autoimmune disease. This exclusion criterion should be&#xD;
             understood as exclusion of subjects having significant medical conditions (such as&#xD;
             cancer, autoimmune diseases) currently under treatment.&#xD;
&#xD;
          -  Acute disease at the time of enrolment. Acute disease is defined as the presence of a&#xD;
             moderate or severe illness with or without fever. Enrolment will be deferred until&#xD;
             condition is resolved. All vaccines can be administered to persons with a minor&#xD;
             illness such as diarrhoea, mild upper respiratory infection with or without low-grade&#xD;
             febrile illness, i.e. oral/ axillary temperature &lt; 37.5 °C (99.5 °F).&#xD;
&#xD;
          -  A subject with body temperature (i.e. fever) &gt; 37.5 °C (99.5 °F).&#xD;
&#xD;
          -  Drug and/or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Son Hoa Hoang, Medicine Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Control of Vaccine and Biologicals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Son Hoa Hoang, Medicine Doctor</last_name>
    <phone>84(4)5595167</phone>
    <email>hoanghoason2005@yahoo.com.vn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thi Son commune health center and Ngoc Son Commune Health Center</name>
      <address>
        <city>Ha nam</city>
        <zip>084</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>son hoa hoang, medicine doctor</last_name>
      <phone>84(4)5595167</phone>
      <email>hoanghoason2005@yahoo.com.vn</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>December 11, 2007</last_update_submitted>
  <last_update_submitted_qc>December 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2007</last_update_posted>
  <responsible_party>
    <name_title>National Institute for Control of Vaccine and Biologicals</name_title>
    <organization>National Institute for Control of Vaccine and Biologicals</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

